2 results
Approved WMOCompleted
To demonstrate that the infliximab serum concentration of Remsima* is non-inferior to the infliximab serum concentration of Remicade , 16 weeks after switch from Remicade to Remsima* in subjects with CD, UC or RA in stable remission for > 30…
Approved WMOWill not start
The purpose of this clinical investigation is to evaluate the effectiveness of modified Sensor designs on the longevity (up to a maximum of 90 days) of the Senseonics Continuous Glucose Monitoring (CGM) System. The investigation will also evaluate…